Author:
He Jin,Blair Alex B.,Groot Vincent P.,Javed Ammar A.,Burkhart Richard A.,Gemenetzis Georgios,Hruban Ralph H.,Waters Kevin M.,Poling Justin,Zheng Lei,Laheru Daniel,Herman Joseph M.,Makary Martin A.,Weiss Matthew J.,Cameron John L.,Wolfgang Christopher L.
Publisher
Ovid Technologies (Wolters Kluwer Health)
Reference44 articles.
1. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States;Rahib;Cancer Res,2014
2. Recent progress in pancreatic cancer;Wolfgang;CA Cancer J Clin,2013
3. Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial;Neoptolemos;Lancet,2017
4. Pancreatic cancer;Hidalgo;N Engl J Med,2010
5. Preoperative/neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages;Gillen;PLoS Med,2010